Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lidocaine ointment in vulvar vestibulitis
NCT00450242Phase 2Terminated
- Sponsor
- University of North Carolina at Chapel Hill
- Start
- Dec 2006
- Primary completion
- Jan 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of lidocaine 10% oropharyngeal spray in vulvar vestibulitis syndrome (VVS), sponsored by University of North Carolina at Chapel Hill. Primary endpoints: Number of Participants Who Report the Ability to Have Intercourse at 8 weeks and Visual Analog Scale for pain with intercourse at 8 weeks. Started Dec 2006; status: terminated.
02
Drugs
lidocaine 10% oropharyngeal spray
03
Conditions
vulvar vestibulitis syndrome (VVS)
Beyond the preview
Go deeper on NCT00450242.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00450242.